TP-6076

TP-6076 is a fully synthetic, next-generation fluorocycline antibiotic of the tetracycline class. It was developed to address serious and life-threatening bacterial infections, particularly those caused by multidrug-resistant Gram-negative pathogens such as carbapenem-resistant Acinetobacter baumannii (CRAB) and Enterobacteriaceae. The drug acts by inhibiting bacterial protein synthesis through binding to the 30S ribosomal subunit, thereby blocking translation and preventing bacterial growth. Preclinical studies demonstrated potent activity against difficult-to-treat Gram-negative bacteria, including strains resistant to other antibiotics in its class. Clinical development included intravenous administration in healthy volunteers; however, further development for Gram-negative infections was discontinued after Phase 1 trials due to strategic reasons rather than safety concerns[1][7][8][9].

Other names

TP 6076TP6076TP-6076